Resensitization in suspected penicillin allergy.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
01 2023
Historique:
revised: 29 07 2022
received: 04 05 2022
accepted: 08 08 2022
pubmed: 7 9 2022
medline: 30 12 2022
entrez: 6 9 2022
Statut: ppublish

Résumé

The diagnosis of allergic reactions to penicillins (AR-PEN) is very complex as there is a loss of sensitization over time, which leads to negative skin tests (STs) and specific IgE in serum, and even to tolerance to the drug involved. However, STs may become positive after subsequent exposure to the culprit drug (resensitization), with the risk of inducing potentially severe reactions. The exact rate of resensitization to penicillins is unknown, ranging from 0% to 27.9% in published studies. To analyze the rate of resensitization in patients with suggestive AR-PEN by repeating STs (retest) after an initial evaluation (IE). Patients with suspected AR-PEN were prospectively evaluated between 2017 and 2020. They underwent STs, and a randomized group also underwent a drug provocation test (DPT) with the culprit. Only patients with negative STs and/or DPT were included. All included cases were retested by STs at 2-8 weeks. A total of 545 patients were included: 296 reporting immediate reactions (IRs) and 249 non-immediate reactions (NIRs). Eighty (14.7%) cases had positive results in retest (RT+): 63 (21.3%) IRs and 17 (6.8%) NIRs (p < 0.0001). The rate of RT+ was higher in anaphylaxis compared with all other reactions (45.8% vs 9.1%, p < 0.0001). The risk of RT+ was higher from the fifth week after IE (OR: 4.64, CI: 2.1-11.6; p < 0.001) and increased with the patient's age (OR: 1.02; CI: 1.01-1.04; p = 0.009). Due to the high rate of resensitization, retest should be included in the diagnostic algorithm of IRs to penicillins after an initial negative study, especially in anaphylaxis, to avoid potentially severe reactions after subsequent prescriptions of these drugs.

Sections du résumé

BACKGROUND
The diagnosis of allergic reactions to penicillins (AR-PEN) is very complex as there is a loss of sensitization over time, which leads to negative skin tests (STs) and specific IgE in serum, and even to tolerance to the drug involved. However, STs may become positive after subsequent exposure to the culprit drug (resensitization), with the risk of inducing potentially severe reactions. The exact rate of resensitization to penicillins is unknown, ranging from 0% to 27.9% in published studies.
OBJECTIVES
To analyze the rate of resensitization in patients with suggestive AR-PEN by repeating STs (retest) after an initial evaluation (IE).
MATERIAL AND METHODS
Patients with suspected AR-PEN were prospectively evaluated between 2017 and 2020. They underwent STs, and a randomized group also underwent a drug provocation test (DPT) with the culprit. Only patients with negative STs and/or DPT were included. All included cases were retested by STs at 2-8 weeks.
RESULTS
A total of 545 patients were included: 296 reporting immediate reactions (IRs) and 249 non-immediate reactions (NIRs). Eighty (14.7%) cases had positive results in retest (RT+): 63 (21.3%) IRs and 17 (6.8%) NIRs (p < 0.0001). The rate of RT+ was higher in anaphylaxis compared with all other reactions (45.8% vs 9.1%, p < 0.0001). The risk of RT+ was higher from the fifth week after IE (OR: 4.64, CI: 2.1-11.6; p < 0.001) and increased with the patient's age (OR: 1.02; CI: 1.01-1.04; p = 0.009).
CONCLUSIONS
Due to the high rate of resensitization, retest should be included in the diagnostic algorithm of IRs to penicillins after an initial negative study, especially in anaphylaxis, to avoid potentially severe reactions after subsequent prescriptions of these drugs.

Identifiants

pubmed: 36067012
doi: 10.1111/all.15508
pmc: PMC10087608
doi:

Substances chimiques

Immunoglobulin E 37341-29-0
Penicillins 0
Sodium Tetradecyl Sulfate Q1SUG5KBD6
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-224

Informations de copyright

© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

Ann Allergy Asthma Immunol. 2008 Jan;100(1):37-43
pubmed: 18254480
J Investig Allergol Clin Immunol. 1996 Jan-Feb;6(1):30-5
pubmed: 8833166
Allergy. 2003 Oct;58(10):961-72
pubmed: 14510712
Allergy. 2020 Jun;75(6):1300-1315
pubmed: 31749148
Allergy. 1999 Sep;54(9):999-1003
pubmed: 10505466
J Allergy Clin Immunol. 1984 Jan;73(1 Pt 1):76-81
pubmed: 6693670
Allergy. 2004 Nov;59(11):1153-60
pubmed: 15461594
Allergy. 2014 Jun;69(6):806-9
pubmed: 24673580
J Allergy Clin Immunol. 1991 Aug;88(2):213-7
pubmed: 1880322
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):196-200
pubmed: 28803185
Br J Dermatol. 2006 Jan;154(1):198
pubmed: 16403125
J Anesth. 2020 Aug;34(4):624-629
pubmed: 32476042
J Allergy Clin Immunol Pract. 2019 Jan;7(1):40-45
pubmed: 30245291
Allergy. 2014 Apr;69(4):420-37
pubmed: 24697291
Allergy. 1995 Jul;50(7):563-7
pubmed: 8588688
J Allergy Clin Immunol. 1999 May;103(5 Pt 1):918-24
pubmed: 10329829
J Allergy Clin Immunol. 2003 May;111(5):1111-5
pubmed: 12743578
Allergy Asthma Proc. 2004 May-Jun;25(3):161-4
pubmed: 15317319
Lancet. 1977 Feb 26;1(8009):466-9
pubmed: 65572
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1648-1657.e1
pubmed: 33253923
Clin Exp Allergy. 2009 May;39(5):726-30
pubmed: 19178535
Allergy. 2019 Sep;74(9):1817-1819
pubmed: 31034613
Clin Exp Allergy. 1996 Mar;26(3):335-40
pubmed: 8729672
Allergy. 2016 Aug;71(8):1103-34
pubmed: 26991315
Arch Intern Med. 2002 Apr 8;162(7):822-6
pubmed: 11926858
Allergy. 2009 Feb;64(2):242-8
pubmed: 19178404
J Pediatr. 1998 Jan;132(1):137-43
pubmed: 9470015
J Investig Allergol Clin Immunol. 2012;22(5):363-71
pubmed: 23101312
Clin Transl Allergy. 2017 Mar 13;7:7
pubmed: 28293415
J Allergy Clin Immunol. 2011 Jan;127(1):218-22
pubmed: 21035175
Allergy. 2016 Dec;71(12):1787-1790
pubmed: 27543745
Allergy. 2001 Sep;56(9):850-6
pubmed: 11551249
Allergy. 2002 Jan;57(1):45-51
pubmed: 11991289
Allergy. 2023 Jan;78(1):214-224
pubmed: 36067012
Ann Allergy Asthma Immunol. 2013 Apr;110(4):267-73
pubmed: 23535091
J Investig Allergol Clin Immunol. 2012;22(1):41-7
pubmed: 22448453
Allergy. 2019 Jan;74(1):14-27
pubmed: 30028512
Acta Anaesthesiol Scand. 2012 Sep;56(8):1042-6
pubmed: 22313451
J Allergy Clin Immunol. 2012 Jan;129(1):263-4; author reply 265-6
pubmed: 21982115
Allergy. 2003 Sep;58(9):854-63
pubmed: 12911412

Auteurs

Inmaculada Doña (I)

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.

Lucia Guidolin (L)

Allergy Unit, Verona University Hospital, Verona, Italy.

Gádor Bogas (G)

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.

Elisa Olivieri (E)

Allergy Unit, Verona University Hospital, Verona, Italy.

Marina Labella (M)

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.

Michele Schiappoli (M)

Allergy Unit, Verona University Hospital, Verona, Italy.

Rocío Sáenz de Santa María (R)

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.

Annarita Dama (A)

Allergy Unit, Verona University Hospital, Verona, Italy.

María Salas (M)

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.

Gianenrico Senna (G)

Allergy Unit, Verona University Hospital, Verona, Italy.

Patrizia Bonadonna (P)

Allergy Unit, Verona University Hospital, Verona, Italy.

María José Torres (MJ)

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Departamento de Medicina, Universidad de Málaga, Málaga, Spain.
Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH